TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17534460
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy for selected high-risk patients with hypertension.
Study: 11588128
Drug: Beta-carotene (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (30 mg daily)
Study: 7987837
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min
Study: 7987837
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP) at 1000 mg/m2 infused over 20 min with SR-2508 at 5 g/m2 infused over 20 min
Study: 2557307
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily fractions to the liver (3.0 Gy external beam radiation, total dose 21.0 Gy) with chemotherapy (Adriamycin 15 mg IV and 5-FU 500 mg IV, 2 hr before treatment on days 1, 3, 5, and 7)
Study: 2557307
Drug: Hyperfractionated whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated whole liver external beam irradiation (1.2 Gy twice daily, 4 hr between treatments, 5 days per week to 24.0 Gy, 10 MV photons) with the same chemotherapy regimen
Study: 1149303
Drug: Apomorphine hydrochloride
Normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine hydrochloride (0.75 mg s.c.)
Study: 1149303
Drug: L-DOPA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DOPA (500 mg p.o.)
Study: 1149303
Drug: Benztropine mesylate
Normalized name: Benztropine Mesylate
DrugBank: Benzatropine (DB00245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benztropine mesylate (1 mg i.m.)
Study: 28618299
Drug: Internet guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet guided self‐help cognitive‐behavioural treatment (ICBT)
Study: 26441220
Drug: Continuous micropump
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous micropump infusion of atropine and pralidoxime chloride
Study: 26441220
Drug: Repeated-bolus doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated-bolus doses of atropine and pralidoxime chloride
Study: 20209468
Drug: Pyruvate supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyruvate supplementation (2 g per day for 4 weeks)
Study: 3934915
Drug: s.c. salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. salbutamol 0.5 mg
Study: 3934915
Drug: Placebo 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mg
Study: 27724833
Drug: Psychotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy for TTM (details on dosage and duration not available)
Study: 21535346
Drug: Sitagliptin/Metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/Metformin FDC
Study: 21535346
Drug: Metformin Monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin Monotherapy
Study: 11786454
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed (Group B)
Study: 11786454
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics prescribed (Group A)
Study: 8597968
Drug: Ilioinguinal-iliohypogastric nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal-iliohypogastric nerve block performed by anaesthetist using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Study: 8597968
Drug: Ilioinguinal-iliohypogastric nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilioinguinal-iliohypogastric nerve block performed by surgeon using 0.25% plain bupivicaine (0.5 ml.kg‐1)
Study: 2527678
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injections (three preprandial injections of short‐acting insulin (NovoPen) plus once daily extended‐acting insulin)
Study: 2527678
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily injections of short‐ and intermediate‐acting insulin
Study: 7286051
Drug: Chlorthalidone 100
Normalized name: chlorthalidone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 100 mg
Study: 334436
Drug: Chlorthalidone 200
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 200 mg
Study: 334436
Drug: Chlorthalidone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (various doses)
Study: 334436
Drug: Chlorthalidone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (higher doses)
Study: 27814327
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of absolute alcohol (ethanol)
Study: 27814327
Drug: 1.5 mL
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of chlorpromazine (25 mg/mL)
Study: 16880018
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire on hair removal practices and psychological impact
Study: 1510408
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg, orally twice daily for 7 days)
Study: 1510408
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg, orally twice daily for 7 days)
Study: 6392936
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nadolol
Study: 6392936
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nadolol and 5 mg bendroflumethiazide
Study: 31655942
Drug: Traditional Lp(a)-lowering
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Lp(a)-lowering approaches (niacin, PCSK9 inhibitors, mipomersen, lomitapide, lipoprotein apheresis)
Study: 27175476
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PGJ) (250 g)
Study: 27175476
Drug: Fermented sour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented sour sobya (FS) (170 g)
Study: 27175476
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of PGJ (150 g) and FS (140 g)
Study: 27175476
Drug: Fresh apricot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh apricot fruits (200 g)
Study: 22685234
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg/d; n = 25)
Study: 17850670
Drug: Tablet PC-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet PC-based video (Trial Two)
Study: 10428345
Drug: 50-g glucose
Normalized name: glucose 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-g glucose challenge test
Study: 2099963
Drug: Defibrotide administered
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide administered orally (400 mg b.i.d. for 15 days)
Study: 2099963
Drug: Defibrotide administered
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide administered intramuscularly (200 mg b.i.d. for 15 days)
Study: 317255
Drug: Clofibate (lipid-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (lipid-lowering substance) administered in a double-blind trial for an average of 5.3 years.
Study: 28929830
Drug: Collaborative intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collaborative intervention process (six weekly sessions)
Study: 17127227
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g t.i.d. of imipenem/cilastatin (group A)
Study: 17127227
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g t.i.d. of meropenem (group B)
Study: 14985312
Drug: PKC412 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC412 150 mg/d
Study: 14985312
Drug: PKC412 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC412 100 mg/d
Study: 14985312
Drug: PKC412 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC412 100 mg/d and 150 mg/d
Study: 14985312
Drug: PKC412 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKC412 50 mg/d, 100 mg/d, 150 mg/d
Study: 9924222
Drug: Bupivacaine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine up to 2 mg kg‐1, infiltrated around the inferior alveolar nerves bilaterally
Study: 9924222
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg i.v. at the start of surgery
Study: 25130262
Drug: 1.4 g
Normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g day(-1) omega-3 PUFAs plus cognitive behavioural case management
Study: 15087034
Drug: HMVP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMVP regimen (hydroxycamptothecin 12 mg/m² d1-d5, mitomycin C 6 mg/m² d1, vindesine 2.5-3 mg/m² d1 and d8, cisplatin 50 mg/m² d2 and d3)
Study: 9058157
Drug: Locoregional targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional targeted chemotherapy only via an arterial catheter (Group A)
Study: 9058157
Drug: Combined locoregional
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined locoregional immuno-chemotherapy via two arterial catheters (Group B)
Study: 7839878
Drug: Traditional anti-diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anti-diabetic medicines (hospital-based trial for about 4 weeks)
Study: 7839878
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (ambulatory basis for up to 16 weeks)
Study: 2944006
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase (250,000 U) followed by i.v. administration of streptokinase (500,000 U) in group 2.
Study: 2944006
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in group 1.
Study: 3351336
Drug: Clobetasol Proprionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol Proprionate ointment
Study: 28751575
Drug: Intranasal lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal lispro insulin (40 IU)
Study: 24069451
Drug: Structured pro-active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured pro-active care by practice nurses (3 monthly review appointments over 2 years)
Study: 19446387
Drug: Epinephrine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (1 mg)
Study: 16397814
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (750 ml total, 250 ml cranberry juice + 500 ml mineral water)
Study: 16397814
Drug: Placebo (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (750 ml total, 750 ml placebo)
Study: 16397814
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (750 ml total, 750 ml cranberry juice)
Study: 16397814
Drug: Placebo (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (750 ml total, 250 ml placebo + 500 ml mineral water)
Study: 11763381
Drug: Finasteride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (1 mg)
Study: 8489204
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of zidovudine five times daily
Study: 8489204
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of zidovudine five times daily
Study: 8489204
Drug: Placebo five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo five times daily
Study: 8489204
Drug: Rerandomized to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rerandomized to zidovudine treatment after week 16
Study: 12633191
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fecal occult blood testing and sigmoidoscopy
Study: 10997423
Drug: Positive oral
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive oral MR contrast media (Magnevist)
Study: 10997423
Drug: Negative oral
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative oral MR contrast media (Abdoscan)
Study: 8233262
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist leuprolide acetate depot for 3 months
Study: 3545094
Drug: Educational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational programme by community child health nurses, visited monthly for six months.
Study: 7989405
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg single oral dose)
Study: 2686576
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride (mean dose 150 +/- 53 mg/d)
Study: 2686576
Drug: Desipramine hydrochloride
Normalized name: Desipramine Hydrochloride
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine hydrochloride (mean dose 153 +/- 55 mg/d)
Study: 28390501
Drug: Internet-based extinction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based extinction therapy (IbET)
Study: 27542131
Drug: Social learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social learning and cognitive behavioral therapy condition
Study: 24602997
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (activation of a sham electrode) under continuous reinforcement (CRF)
Study: 24602997
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (activation of a sham electrode) under partial reinforcement (PRF)
Study: 20712749
Drug: Lamotrigine (up-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (up-titrated to 400 mg/day)
Study: 20712749
Drug: Lithium (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (doses adjusted to obtain serum levels of 0.5-1.0 mmol/L)
Study: 17344507
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (45 mg elemental Zn/d) for 12 months
Study: 1427379
Drug: Miglitol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (100 mg)
Study: 27832555
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 0.2 µg/ml effect-site concentration
Study: 27832555
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 0.4 µg/ml effect-site concentration
Study: 23974276
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone therapy (Omnadren 250) for 9 weeks
Study: 19365786
Drug: Clarithromycin treatment
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin treatment for 3 months
Study: 16877720
Drug: Paclitaxel (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (weekly for 24 weeks after initial treatment for those with objective response or stable disease)
Study: 11424516
Drug: YGD capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGD capsules (three capsules before each main meal for 10 days)
Study: 11424516
Drug: YGD capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGD capsules (three capsules before each main meal for 45 days)
Study: 11424516
Drug: YGD capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGD capsules (active treatment for 12 months)
Study: 11424516
Drug: YGD capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGD capsules
Study: 7712308
Drug: UDCA (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (450 mg/day) for 6 months
Study: 10813709
Drug: Intraarterial cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial cisplatin infusion
Study: 2676224
Drug: Intravenous cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin infusion
Study: 2676224
Drug: Intraarterial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial and intravenous cisplatin infusions
Study: 28870
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (CZP) with 60 ml of water
Study: 28870
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (CZP) with 60 ml of magnesium aluminum hydroxide (Maalox)
Study: 26305064
Drug: Rivastigmine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (single oral dose)
Study: 26305064
Drug: Rivastigmine (1-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (1-month treatment)
Study: 16690717
Drug: Oral-only breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-only breathing (nose clip)
Study: 9459317
Drug: Third generation
Normalized name: Third generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third generation oral contraceptives (OCs)
Study: 9459317
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral contraceptives (OCs)
Study: 798592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Asa foetida and Nux vomica (0.01% alcoholic dilution)
Study: 28760751
Drug: Multitarget therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitarget therapy (tacrolimus, 2‐3mg/d; mycophenolate mofetil, 0.50‐0.75 g/d; prednisone, 10mg/d)
Study: 28760751
Drug: Azathioprine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2 mg/kg per day) plus prednisone (10 mg/d)
Study: 31580800
Drug: Multitarget therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitarget therapy
Study: 9424001
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg p.o.
Study: 9424001
Drug: Metoclopramide 30
Normalized name: metoclopramide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 30 mg p.o.
Study: 9424001
Drug: Metoclopramide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 60 mg p.o. (after dose increase)
Study: 3743627
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin (1.2 g)
Study: 3743627
Drug: Aspirin tablets
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin tablets (1.2 g)
Study: 10893655
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin
Study: 1576068
Drug: Aspirin tablets
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin tablets
Study: 26967681
Drug: Desipramine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 200 mg
Study: 22138847
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing and direct periodontal intrapocket application of 15% metronidazole‐based gel in two sites (>5 mm in depth)
Study: 21090335
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Sishencong, Baihui, Shenting, etc.), once daily for 2 months.
Study: 21090335
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/d), administered orally for 2 months.
Study: 16178494
Drug: Ciprofloxacin/β-lactam combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin/β-lactam combination
Study: 10577438
Drug: Niacin treatment
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin treatment (100 mg to 1000 mg daily)
Study: 1752603
Drug: CC-hMG combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-hMG combination cycle
Study: 1752603
Drug: CC-hMG cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-hMG cycle
Study: 7040192
Drug: Progestogen only
Normalized name: vaginal ring with progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen only (Lynestrenol 0.5 mg)
Study: 7040192
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (ethinyl estradiol 50 micrograms + lynestrenol 2.5 micrograms)
Study: 31858136
Drug: Shorter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter treatment duration (5-9 days)
Study: 31858136
Drug: Longer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer treatment duration (10-15 days)
Study: 30261877
Drug: Intermittent Screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Screening and Treatment (ISTp)
Study: 30261877
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment (IPTp)
Study: 27381286
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction regimen of etanercept (50 mg/week for 4 weeks followed by 25 mg/week for 8 weeks)
Study: 27381286
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of etanercept (50 mg/week for 12 weeks)